Bertis named as an Excellent Corporation R&D Center

- In recognition of its R&D capabilities and technological competitiveness accumulated over 10 years, the company was designated as an Excellent Corporation R&D Center in the second half of 2021

- Bertis CEO Seung Man Han said, “As a leading company of proteomics, the company will endeavor to contribute to the national healthcare and the industry by accelerating the implementation of precision medicine.”

< Bertis CEO Seung Man Han (left), and Head of the biomarker research institute Un Beom Kang (right), are taking commemorative photos after receiving certificates with signboards of the Excellent Corporation R&D Center in the second half of the 2021 ceremony on 23rd December >

Bertis, a proteomic-based precision medicine development company, announced on 27th December 2021 that its biomarker research institute, located in Bundang-gu Sungnam-si Gyeonggi-do, was selected for an Excellent Corporation R&D Center (ECRC).

The Ministry of Science and ICT’s Excellent Corporation R&D Center award was designed to encourage qualitative growth of technological innovation in domestic companies. The authority discovers and supports research institutes with exceptional R&D capabilities and technological innovation activities.

Bertis’ research institute was selected as an ECRC in recognition of its proteomics research capabilities and technological competitiveness accumulated over the past decade after a strict screening process. The company will maintain its status as an ECRC for the next three years and will benefit from government rewards and granting additional points for national R&D projects along with the provision of a certificate and a signboard of the Minister of Science and ICT.

Bertis has built 25 million protein libraries through more than a decade of research and has proven its position as a pioneer in proteomics technology by commercializing the world's first proteomic-based breast cancer blood test solution ‘Mastocheck’. The company operates two corporate-affiliated research institutes in Seongnam and Yongin, Gyeonggi-do. It focuses on developing companion diagnostics and precision medicine by developing multi-marker diagnostic technologies for various diseases such as pancreatic cancer, ovarian cancer, and cardiovascular diseases.

Bertis CEO Seung Man Han said, "We feel rewarded and proud of the award in recognition of proteomics R&D capabilities accumulated over the past. As a leading company of the domestic proteomics industry, we will commit to protect public health from diseases and contribute to innovation and development of the healthcare industry in Korea."